Wegovy in the UK: NHS Availability, Cost & Alternatives 2026

Overview

Wegovy (semaglutide 2.4mg) was approved by MHRA for weight management and is now available in the UK. However, access through the NHS is limited, leading many to explore private options. This guide covers the current state of Wegovy availability in the UK, eligibility criteria, costs, and alternatives — helping you understand your options in 2026.

Wegovy NHS Availability: Current Status

NICE (National Institute for Health and Care Excellence) has approved Wegovy for NHS use, but access remains limited due to supply constraints and strict eligibility criteria. NHS England has been rolling out Wegovy through specialist weight management services, but demand far exceeds supply. The medication is being prioritized for patients with the highest clinical need. In practice, many patients who meet eligibility criteria still cannot access Wegovy through the NHS due to local commissioning decisions and supply shortages. This has led to a robust private market for Wegovy and alternatives.

NHS Eligibility Criteria

To access Wegovy through the NHS, patients must meet NICE criteria. The primary requirements are: BMI of 35 or above, OR BMI of 30-34.9 with at least one weight-related health condition (type 2 diabetes, high blood pressure, heart disease, etc.). Additional requirements include: referral to and ongoing support from specialist weight management services, and commitment to lifestyle changes alongside medication. Wegovy is typically limited to 2 years of NHS treatment. After this period, patients may need to transition off the medication or self-fund continued treatment. Not all areas have equal access — availability depends on local NHS trust decisions.

• BMI ≥35, OR BMI ≥30 with weight-related conditions
• Must be under specialist weight management services
• Commitment to diet and exercise alongside medication
• Typically limited to 2 years on NHS
• Local availability varies significantly

Private Prescription Costs

Most UK users access Wegovy through private prescriptions, either from private clinics or telehealth services. Private Wegovy costs approximately £150-300 per month depending on dose, with the full 2.4mg maintenance dose at the higher end. Initial consultations typically cost £50-150 additionally. Ongoing monthly follow-ups may be required. Several telehealth services have launched specifically for weight loss medications, offering convenient online consultations and home delivery. Competition has somewhat reduced prices, but costs remain significant for long-term treatment. Some private health insurance policies now cover weight loss medications, though this varies significantly by provider and plan.

• Monthly cost: £150-300 depending on dose
• Initial consultation: £50-150
• Follow-up appointments: Often included or £30-50
• Telehealth services: Usually most convenient option
• Insurance: Some policies now cover, check your plan

How to Get Wegovy Privately

The most common pathway to private Wegovy in the UK is through licensed telehealth services. The process typically involves: completing an online health questionnaire, video or written consultation with a prescribing clinician, verification of eligibility and safety checks, and prescription issued to a partnered pharmacy. Popular services include specialist weight management telehealth platforms. Wegovy is also available through traditional private clinics and some private GPs. Ensure any service you use has prescribing clinicians registered with the GMC and appropriate clinical governance. Be wary of services that don't require proper medical assessment before prescribing.

Mounjaro as an Alternative

Mounjaro (tirzepatide) has become available in the UK and is often preferred over Wegovy for weight loss. Clinical trials showed tirzepatide produces approximately 5-10% more weight loss than semaglutide. NICE has approved Mounjaro for type 2 diabetes, and weight loss approval (as Zepbound) is expected. Private access to Mounjaro is available through similar telehealth channels as Wegovy. Costs are comparable, though Mounjaro is sometimes slightly more expensive. Many UK users who can access either medication are choosing Mounjaro based on the efficacy data. The side effect profiles are similar, though some users tolerate one better than the other.

Compounded Semaglutide: The Gray Area

Compounded semaglutide is available in the UK through certain providers, though its legal status is complex. Compounding pharmacies can produce semaglutide under specific circumstances, but the regulatory framework is different from licensed medications like Wegovy. Costs are typically 30-50% lower than brand Wegovy. Quality and consistency concerns exist — not all compounding sources are equivalent. Some telehealth services offer compounded options alongside branded medications. Users should understand they're assuming additional risk compared to licensed products. The compounded market is smaller in the UK than in the US due to different regulatory environments.

Other NHS Weight Management Options

If Wegovy isn't available, other NHS weight management options exist. Saxenda (liraglutide) is a daily injectable GLP-1 that has been available on NHS longer than Wegovy, though it's generally considered less effective. Orlistat (Xenical/Alli) blocks fat absorption and is available on NHS and over-the-counter, but effectiveness is modest. Specialist weight management services offer comprehensive programs including dietary support, exercise guidance, and psychological support. Bariatric surgery remains an option for those with BMI ≥40 or ≥35 with significant comorbidities. Many patients combine multiple approaches.

• Saxenda (liraglutide): Daily GLP-1 injectable, less effective than semaglutide
• Orlistat: Blocks fat absorption, modest results
• Weight management services: Diet, exercise, psychological support
• Bariatric surgery: For severe obesity with comorbidities
• Lifestyle interventions: Often required alongside any medication

Tips for UK Access

Based on community experiences, here are practical tips for accessing weight loss medications in the UK. Start by speaking with your GP — even if NHS access is unlikely, they can provide referrals and documentation that private services require. Research telehealth providers carefully; look for GMC-registered prescribers and proper clinical governance. Compare prices across multiple services, as costs vary significantly. Be prepared for ongoing costs — this is typically a long-term treatment. Consider Mounjaro if available, as many users report better results. Join UK-specific support communities on Reddit and Facebook for current information about availability and trusted providers.

References

1. NICE Technology Appraisal Guidance: Semaglutide for managing overweight and obesity (2023)
2. NHS England: Weight Management Medicines (2024)
3. MHRA: Wegovy (semaglutide) UK Approval (2023)